Finerenone CKD uptake reveals the cardio-renal-metabolic prescribing gap

Reading the signal

Finerenone is a non-steroidal mineralocorticoid receptor antagonist with cardiovascular and renal outcome benefit in chronic kidney disease patients with type 2 diabetes. The pivotal trials (FIDELIO-DKD, FIGARO-DKD) established a clear benefit profile across cardiovascular events and CKD progression endpoints. Real-world uptake to date has been slower than the benefit profile would suggest.

Real-world data from claims and EHR analyses shows several drivers:

• Specialist coordination is uneven. CKD-with-diabetes patients are typically followed by some combination of primary care, cardiology, nephrology and endocrinology. Finerenone introduction often requires alignment across two or three of these
• Regimen integration is operationally complex. Finerenone is added on top of ACE/ARB, often alongside SGLT2 inhibitors and increasingly alongside GLP-1, with potassium monitoring requirements that some specialty workflows do not handle natively
• Awareness gaps persist in primary care, where many cardio-renal-metabolic patients are managed without specialist referral

The slow uptake is not for lack of clinical benefit. It is for lack of operational pathway integration.

Commercial implications

For sponsors with cardio-renal-metabolic assets in development or in commercial life:

1. Multi-specialty pathway integration is part of the launch model. Assets that span cardiology, nephrology and endocrinology need launch operating models that engage all three specialties simultaneously, not sequentially.
2. Primary care integration is the under-invested layer. Many cardio-renal-metabolic patients are not under specialist care, and the primary care engagement model is the rate-limit on broader uptake.
3. The combination-with-SGLT2 and combination-with-GLP-1 evidence base is becoming commercially decisive. Real-world cohorts on combination use, safety in combination, and outcomes in combination are shaping the prescribing decision more than the original monotherapy data.

What we are watching

• Real-world combination-use cohort data, particularly finerenone-plus-SGLT2 and finerenone-plus-GLP-1 outcomes
• Primary care integration initiatives and what works versus what does not in driving cardio-renal-metabolic asset uptake outside specialist care
• Adjacent cardio-renal-metabolic pipeline (novel non-steroidal MRAs, dual mechanism assets) and how these new entrants navigate the cross-specialty coordination problem